Tumor lysis syndrome after hydrocortisone treatment in metastatic melanoma: a case report and review of the literature

Am J Med Sci. 2002 Mar;323(3):155-7. doi: 10.1097/00000441-200203000-00007.

Abstract

Tumor lysis syndrome (TLS) is 1 of the complications that usually follows chemotherapy treatment of myelo-lymphoproliferative diseases. Corticosteroids (CS) could also induce TLS in this type of malignancies. On the other hand, TLS in solid tumors is less frequent, and CS treatment was never reported to be associated with TLS in solid tumor. Here we report the first case of TLS in a solid tumor (melanoma) after CS treatment.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / therapeutic use
  • Blood Chemical Analysis
  • Fatal Outcome
  • Female
  • Humans
  • Hydrocortisone / adverse effects*
  • Hydrocortisone / therapeutic use
  • Melanoma / drug therapy*
  • Melanoma / physiopathology
  • Middle Aged
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / physiopathology
  • Tumor Lysis Syndrome / etiology*

Substances

  • Anti-Inflammatory Agents
  • Hydrocortisone